DoD Autism, Clinical Trial Award
ID: 353176Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353176
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a grant opportunity titled "DoD Autism, Clinical Trial Award" aimed at advancing research in Autism Spectrum Disorders (ASD). This grant supports the rapid implementation of clinical trials that can significantly impact the treatment or management of ASD, with a strong encouragement for applications to address specific areas of interest outlined for FY24. The total estimated funding for this program is $6.56 million, with the expectation of awarding two grants, and applications are due by August 15, 2024, following a pre-application process due by May 16, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    FY24.pdf
    The Department of Defense has issued a Clinical Trial Award for the Fiscal Year 2024 under the Autism Research Program (ARP) specifically targeting early-career investigators. Eligible principal investigators (PIs) must meet specific criteria by the application deadline of August 15, 2024, including dedicating at least 50% of their efforts to the proposed clinical research. Additionally, candidates should be within seven years of obtaining a terminal degree (excluding time spent in residency or family medical leave) and have completed a postdoctoral training position by the deadline. The document requires the PI to certify their eligibility and provides sections for both PI and an official from their organization to validate the information. This initiative aims to foster research addressing autism while ensuring that emerging researchers are actively engaged in clinical investigations.
    HT942524ARPCTA_GG.pdf
    The Department of Defense (DOD) has announced the Fiscal Year 2024 Autism Clinical Trial Award under the Autism Research Program (ARP), with funding aimed at advancing research in Autism Spectrum Disorders (ASD). The total funding allocated for FY24 is $15 million, specifically to support impactful clinical trials relevant to service members, veterans, and the general public. The application process is structured in two steps: a pre-application due by May 16, 2024, followed by full applications by August 15, 2024, contingent on invitation following pre-screening. Research proposals should align with specified areas of interest, including community-led interventions, pharmacological treatments, and mental health issues in autistic populations. Researchers are encouraged to establish collaborations to enhance the research's impact. The award supports trials with up to $1.9 million in direct costs, allowing higher amounts for collaborations involving early-career investigators. This initiative reflects the government’s commitment to improving outcomes for individuals with ASD, signifying a critical funding opportunity for clinical research in this field. Applications must adhere to stringent guidelines outlined in the funding announcement to be eligible for review and funding.
    Similar Opportunities
    DoD VRP, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the FY24 Vision Clinical Trial Award to fund innovative clinical trials aimed at addressing eye injuries and visual dysfunctions related to military service. This grant opportunity supports early-phase clinical trials that evaluate new products, pharmacologic agents, and devices, with a focus on improving treatment outcomes for service-connected visual impairments. With an estimated total program funding of $2.56 million and an anticipated award amount of up to $1.6 million per application, interested applicants must submit their pre-applications by July 11, 2024, and full applications by November 8, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Toxic Exposures Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Toxic Exposures Clinical Trial Award under the Toxic Exposures Research Program (TERP). This grant aims to support the rapid implementation of clinical trials that address health outcomes related to military-related toxic exposures, with a focus on prevention, treatment, and management of associated symptoms and diseases. The program emphasizes the importance of collaboration between the Department of Defense and the Department of Veterans Affairs, seeking proposals that align with specific program goals and topic areas, such as neurotoxin exposure and Gulf War Illness. The total estimated funding for this initiative is $10.4 million, with applications due by November 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DOD Glioblastoma, Resource Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Resource Development Award, aimed at enhancing research capabilities for glioblastoma, a malignant brain tumor. This grant supports the development of preclinical model systems that improve the understanding and treatment of glioblastoma, with a focus on innovative approaches such as animal models, organoids, and patient-derived xenografts. With a total funding pool of $4 million, the program anticipates awarding up to five grants, each capped at $500,000 over three years. Interested applicants must submit a pre-application by November 6, 2024, followed by a full application due by November 20, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)" aimed at promoting research on Autism Spectrum Disorders (ASD). This initiative encourages applications that investigate various aspects of ASD, including its etiology, epidemiology, diagnosis, and service delivery methods, through small, well-defined projects that can be completed within two years. The R03 grant program is particularly significant as it addresses a critical public health issue affecting many individuals and families, allowing for both clinical and non-clinical trials without the requirement for preliminary data in pilot studies. Interested applicants can apply for grants of up to $50,000, with the application deadline set for November 16, 2024. For further details, applicants may contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement page at http://grants.nih.gov/grants/guide/pa-files/PA-21-199.html.
    Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Autism Spectrum Disorders (ASD) under the title "Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)." This initiative aims to support research that elucidates the etiology, epidemiology, diagnosis, and optimal service delivery methods related to ASD, encouraging applications from a diverse range of eligible organizations, including higher education institutions, non-profits, and tribal governments. The research projects may include clinical trials exploring biological or behavioral processes associated with ASD, with a focus on areas such as epidemiological studies, screening methods, and services research to enhance care for individuals with ASD. Applications are due by January 25, 2025, and interested parties can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries or assistance.
    Toxic Exposures Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Toxic Exposures Translational Research Award (TRA) to support research on adverse health outcomes related to military toxic exposures. This grant aims to facilitate translational research that bridges basic science and clinical applications, focusing on developing diagnostics, treatment strategies, and understanding exposure mechanisms to improve health care for service members and their families. With an estimated total program funding of $12.8 million and the expectation of awarding six grants, applicants must submit a pre-application by August 13, 2024, followed by a full application due by November 7, 2024. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD VRP, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Vision Translational Research Award (VRP TRA) to support innovative translational research aimed at advancing the prevention, diagnosis, and treatment of eye injuries and visual dysfunction associated with military service. This grant opportunity encourages projects that establish a clear path for transforming promising discoveries into clinical applications, including new drugs and devices, with a focus on collaboration with regulatory experts to facilitate the approval process. With an estimated total program funding of $1.6 million and the expectation of one award, interested applicants must submit a pre-application by July 11, 2024, followed by a full application by November 8, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Glioblastoma, Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Hypothesis Development Award, aimed at funding innovative research to improve glioblastoma patient outcomes. This grant supports exploratory projects that address significant issues in glioblastoma research, particularly in areas such as drug delivery and biomarker identification, without requiring preliminary data. The total estimated funding for this program is approximately $4.64 million, with an expected 13 awards to be made, each with a funding limit of $200,000 for single principal investigators and $300,000 for partnering teams, over a performance period of up to two years. Interested applicants must submit a Letter of Intent by November 6, 2024, followed by a full application by November 20, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.
    Research on Autism Spectrum Disorders (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on Autism Spectrum Disorders (ASD) through the R21 grant mechanism, aimed at elucidating the etiology, epidemiology, diagnosis, and service delivery methods related to ASD. This initiative encourages exploratory and developmental research without the need for preliminary data, allowing for innovative studies on genetic and environmental factors, early diagnosis, brain mechanisms, and cognitive skills. The total budget for projects is capped at $275,000 over two years, and applications are accepted from a wide range of eligible entities, including educational institutions and nonprofit organizations. Interested applicants must submit their proposals electronically via Grants.gov by November 16, 2024, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for any inquiries regarding the funding announcement.
    Autism Research Consortium
    Active
    Health Resources and Services Administration
    The Health Resources and Services Administration (HRSA) is forecasting a grant opportunity titled "Autism Research Consortium," aimed at establishing a consortium of research institutions to enhance the evidence base for effective interventions and services for children and adolescents with autism and other developmental disabilities. Eligible applicants include public and private entities, such as research centers, faith-based organizations, and tribal entities, with no cost-sharing or matching requirements. This initiative is critical for advancing health services and support systems for affected populations, with an estimated total program funding of $4.8 million and an award ceiling of $960,000 for up to five awards. Interested parties can reach out to Deborah Quint Shelef and Emmie Perchak at AutismRC@hrsa.gov or by phone at (240) 460-5221, with proposals expected to be submitted by March 10, 2025, and project start dates anticipated for September 1, 2025.